Evidence map›Paper›PMID 39335031›Full record

ArticleAntibiotics (Basel, Switzerland)2024

Safety and Tolerability of ShigActive™, a

Wilbur H Chen, Joelle Woolston, Silvia Grant-Beurmann, Courtney K Robinson, Garima Bansal, Joseph Nkeze, Jasnehta Permala-Booth, Claire M Fraser, Sharon M Tennant, Mallory C Shriver and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Bacteriophage Therapy AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
  4. Shigellosis.Lancet (London, England) · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wilbur H ChenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-7741-5536
Joelle WoolstonIntralytix, Inc., Columbia, MD 21046, USA.
Silvia Grant-BeurmannInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-5713-9212
Courtney K RobinsonIntralytix, Inc., Columbia, MD 21046, USA.
Garima BansalCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Joseph NkezeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jasnehta Permala-BoothCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Claire M FraserInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-1462-2428
Sharon M TennantCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-0651-5748
Mallory C ShriverCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0009-0006-6536-3218
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-0894-4009
Yuanyuan LiangCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Karen L KotloffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-1808-6431
Alexander SulakvelidzeIntralytix, Inc., Columbia, MD 21046, USA.
Jennifer A SchwartzIntralytix, Inc., Columbia, MD 21046, USA.ORCID 0000-0001-8239-8857

Funding

Bacteriophage-based approach for managing Shigella infectionsU01AI148054 · NIAID · INTRALYTIX, INC. · PI CHEN, WILBUR H., FRASER, CLAIRE M. · 2020 to 2024
$6.9M
NIAID NIH HHS U01 AI148054NIH/NIAID U01AI148054
6 · The paper itself

Abstract

Bacterial diseases of the gastrointestinal (GI) tract continue to be a major worldwide cause of human morbidity and mortality. Among various enteric pathogens,

Indexed as

alternative antibacterialsbacteriophagebacteriophage therapymicrobiomesafetyshigella

Identifiers

PMID39335031
PMCPMC11429168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.